Concluding Remarks

Abstract

Despite to the exciting results obtained in preclinical studies, these have been not always confirmed in the clinical setting, in which different mechanisms of escape are active. A significant number of patients are resistant, whereas those who respond have minimal benefits. A tumor resistance and also significant side effects including toxicity can occur. It is unrealistic to expect a single agent to be efficacious in the treatment of hematological malignancies. Antiangiogenic agents will have to be used in combination with conventional agents or with other antiangiogenic drugs. Angiogenesis inhibition prolongs progression-free survival, but has only small effects on overall survival, the remissions are partial or patients develop resistance to the treatment. Further research should provide new useful therapeutic approaches and increase options for patients with resistant or refractory disease.